Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 290

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

· 2019 · New England Journal of Medicine

Abstract

People with type 2 diabetes (T2d) are at high risk for adverse cardiovascular (cV) outcomes and progressive decline in renal function. In comparison with the general population, they are 2 to 4 times more likely to be hospitalised or to die from cV causes, including atherosclerotic cV disease (AScVd) and heart failure.1-3 Approximately one third of patients with T2d who develop heart failure have no history of prior coronary heart disease, and while careful control of modifiable cV risk factors can ameliorate risk of death, myocardial infarction (mI) and stroke, the incidence of heart failure in T2d remains consistently higher than that of matched controls.2,3 Therefore, prevention and treatment of these cV complications is fundamental to the management of T2d. Until recently, the primary requirement for trials of drug therapy for T2d has been to show glucose-lowering efficacy and safety. However, concerns over the cV safety of some more recently introduced antihyperglycaemic agents prompted the US Food and drug Administration (FdA) to mandate that from 2008 all new drugs should also be tested for cV safety.4 Furthermore, in the light of data from these cV outcomes trials, new 2018 recommendations for antihyperglycaemic therapy for adults with T2d include early incorporation of an agent proven to reduce major adverse cV events (mAce) and/or cV mortality.5 most cV outcomes trials have shown a neutral effect of antihyperglycaemic agents on cV events. However, well powered randomised controlled trials have demonstrated that the sodium-glucose co-transporter-2 (SGLT-2) inhibitors have favourable effects on cV and renal outcomes, which remain consistent across a broad range of patient subgroups.4,6-8 The most recent of these studies is the Dapagliflozin Effect on Cardiovascular Events Thrombolysis in Myocardial Infarction 58 (decLAreTImI 58) trial, which was designed to evaluate the effects of dapagliflozin on cV and renal outcomes in a broad population of patients with T2d, including those with or without AScVd.8 The results of decLAre-TImI 58, which are summarised in this article, were presented at the 2018 Scientific Sessions of the American Heart Association in November.9

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmc1902837

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 290

Metadata

Venue
New England Journal of Medicine
Published
2019-05-09
Volume
380
Issue
19
Pages
1880-1882
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2980595514
Cited by
290
References
9
FWCI
37.17
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. https://app.cochat.ai/papers/10.1056/nejmc1902837
The paper
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. (2019). New England Journal of Medicine. https://doi.org/10.1056/nejmc1902837

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.